Biocytogen Pharmaceuticals (Beijing) (HKG:2315) expects a net profit of between 27.3 million yuan and 37.3 million yuan for the year 2024, compared with a loss of around 383 million yuan a year prior, a Friday filing with the Hong Kong bourse said.
The pharmaceutical company attributed the anticipated turnaround to profit mainly to a higher sales revenue from the antibody discovery business, a higher revenue contribution from the gene editing animal model business, and a significant decline in R&D investment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。